Clinical Trials Browser

Phase 2 × Olanzapine × Gastrointestinal × Clear all

NCT05705492 2026-01-21

Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer

Phase 2 Recruiting

Gastrointestinal

Anorexia, Cachexia, Esophageal Neoplasms, Neoplasms, Colorectal Neoplasms, Weight Loss

NCT03575637 2018-07-03

Olanzapine Improves the Chemotherapy Tolerance of Advanced Gastric Cancer

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms